FINWIRES · TerminalLIVE
FINWIRES

ASX:CSL

12 stories mentioning ASX:CSL

Every FINWIRES story that references ASX:CSL, newest first.

Asia

CSL Unit Signs Five-Year Lease Contract with Clever Culture Systems for APAS Independence Instrument

CSL's (ASX:CSL) CSL Behring subsidiary signed a five-year contract with Clever Culture Systems (ASX:CC5) for the lease of an APAS Independence instrument and environmental monitoring analysis modules, according to a Tuesday filing with the Australian bourse.APAS Independence is an instrument that automates the imaging, interpretation, and reporting of microbial growth on culture plate media for labs.The contract will be paid in monthly installments, with an initial minimum non-cancellable period of six months following the start of the company's formal validation, which must occur on or before Dec. 31, the filing said.CSL shares rose 1% in morning trade on Tuesday, while Clever Culture Systems shares were up 5%.

ASX:CC5ASX:CSL
Asia

ASX Midday Sector Update: Healthcare Stocks Jump, Materials Sector Struggles

Healthcare stocks jumped nearly 3% at midday Friday.CSL (ASX:CSL) gained 4% in recent trade.Meanwhile, the materials sector struggled, shedding nearly 2%.BHP Group (ASX:BHP) shares fell nearly 2% in recent trade.

ASX 200ASX:BHPASX:CSL
Asia

ASX Midday Sector Update: Information Technology Stocks Jump, Healthcare Sector Falls

Information technology stocks advanced more than 5% at midday Monday.Xero (ASX:XRO) gained 8% in recent trade.On the flip side, the healthcare sector struggled, shedding nearly 2%.CSL (ASX:CSL) shares fell almost 2% in recent trade.

ASX 200ASX:CSLASX:XRO
Asia

ASX Biggest Losers

Here are the ASX-listed companies with the biggest losses on Friday.Energy Resources of Australia (ASX:ERA): -20%, AU$0.002Champion Iron (ASX:CIA): -5%, AU$4.54Superloop (ASX:SLC): -5%, AU$3.42Weebit Nano (ASX:WBT): -4%, AU$7.05Helia Group (ASX:HLI): -3%, AU$4.84GemLife Communities Group (ASX:GLF): -3%, AU$4.45Karoon Energy (ASX:KAR): -3%, AU$1.94Viva Energy Group (ASX:VEA): -2%, AU$2.11Ryman Healthcare (ASX:RYM): -2%, AU$1.88CSL (ASX:CSL): -2%, AU$96.05

ASX 200ASX:CIAASX:CSLASX:ERAASX:GLFASX:HLIASX:KARASX:RYMASX:SLCASX:VEAASX:WBT
Asia

CSL Says CEO Indirectly Acquires Nearly AU$108,000 Worth of Shares

CSL (ASX:CSL) said Chief Executive Gordon Naylor indirectly acquired 1,100 CSL ordinary shares in an on-market purchase on Wednesday for a consideration of AU$107,800, according to a Thursday Australian bourse filing.Naylor-Stewart Investments, as trustee for the Naylor-Stewart Family Trust, holds the shares.CLS's shares fell almost 2% in recent trading on Thursday.

ASX:CSL
Asia

CSL Enters Agreement to Boost Influenza Pandemic Preparedness in Latin America, Caribbean

CSL (ASX:CSL) signed a multi-year agreement with the Pan American Health Organization to boost preparedness for potential influenza pandemics in Latin America and the Caribbean, according to a Wednesday statement.Under the deal, CSL Seqirus has reserved "millions" of vaccine doses that participating countries across the region can order if an influenza pandemic is declared, the company said.CSL Seqirus will collaborate with Argentine production partner Sinergium Biotech to ensure rapid manufacturing and delivery of the vaccines if required.CSL shares advanced 1% in recent Wednesday trade.

ASX:CSL
Asia

CSL's Fiscal-Year Earnings Guidance Downgrade Not Surprising, Jefferies Says

CSL's (ASX:CSL) fiscal-year earnings guidance downgrade was not surprising with the documented issues in immunoglobulin in the US and albumin in China, Jefferies said in a Monday note.The biotechnology company now expects fiscal-year revenue of around $15.2 billion and net profit after tax adjusted to exclude amortization of around $3.1 billion, both on a constant-currency basis.The revision is mainly due to a $300 million hit from excess immunoglobulin inventory in US hospitals and a $200 million shortfall from aggressive albumin price competition in China.However, Jefferies believes that both markets remain underpenetrated, indicating potential growth for the industry in the medium term.Following the downgrade, Jefferies wants to see if the company can provide a clear profit growth outlook for fiscal years 2027 and 2028.The firm maintained its buy rating on CSL and lowered its price target to AU$195 from AU$212.CSL shares fell 2% in midday trade on Tuesday and earlier hit their lowest since October 2015.

ASX:CSL
Asia Markets

Australian Shares Retreat; CSL Cuts Fiscal Year 2026 Outlook, Flags $5 Billion of Additional Impairments

Australian shares retreated on Monday amid reports that the process to reach a peace agreement between Iran and the US had stalled over the weekend.The S&P/ASX 200 Index fell 0.49%, or 42.60 points, to close at 8,701.80.Brent crude oil futures rose over 4% to trade around $105 per barrel after the US rejected Iran's response to a US proposal to end the conflict and reopen shipping through the Strait of Hormuz.On the domestic front, the total number of dwellings approved in Australia fell around 11% to 17,300 in March, seasonally adjusted, from 19,339 in the previous month, according to final figures released by the Australian Bureau of Statistics.In company news, CSL (ASX:CSL) lowered its guidance for fiscal 2026 and expects to recognize about $5 billion of additional non-cash, pre-tax impairments across fiscal 2026 and 2027 beyond those the company disclosed earlier this year.The biotechnology company now expects fiscal 2026 revenue of around $15.2 billion and net profit after tax adjusted to exclude amortization of around $3.1 billion, both on a constant-currency basis. Its shares closed down 15%, earlier hitting their lowest since December 2016.Dyno Nobel (ASX:DNL) reported fiscal first-half earnings of AU$0.089 per share, excluding individually material items, up from AU$0.046 a year earlier. Revenue from ordinary activities for the six months ended March 31 was AU$1.9 billion, compared with AU$2.25 billion a year earlier. It shares rose 7% on close after earlier hitting their highest since January 2023.Lastly, Inghams Group (ASX:ING) reaffirmed its fiscal 2026 guidance for underlying earnings before interest, taxes, depreciation, and amortization of AU$180 million to AU$200 million. Its shares jumped 7% on market close.

ASX 200ASX:CSLASX:DNLASX:ING
Asia

CSL Cuts Fiscal 2026 Outlook, Flags $5 Billion of Additional Impairments; Shares Hit Nine-Year Low

CSL (ASX:CSL) lowered its guidance for fiscal 2026 and expects to recognize about $5 billion of additional non-cash, pre-tax impairments across fiscal 2026 and 2027 beyond those the company disclosed earlier this year, according to a Monday filing with the Australian bourse.The biotechnology company now expects fiscal 2026 revenue of around $15.2 billion and net profit after tax adjusted to exclude amortization (NPATA) of around $3.1 billion, both on a constant-currency basis.In February, it guided for 2% to 3% growth in revenue and 4% to 7% growth in NPATA.The $5 billion of additional impairments include CSL Vifor intangible assets, including the product portfolio, as well as under-utilized property, plant and equipment, the company said.CSL flagged a roughly $300 million fiscal 2026 revenue impact from its "normalization of channel inventory" for US immunoglobulin, a roughly $200 million hit from albumin in China, and an impact of about $150 million from other factors including the Middle East conflict."Our growth initiatives are working, but the financial benefits will take longer than previously anticipated to materialize," said interim CEO Gordon Naylor.The company's shares tumbled 17% in recent Monday trade and earlier hit their lowest since December 2016.

ASX:CSL
Asia

Market Chatter: CSL, Resmed, Cochlear Lead Losses on ASX

CSL (ASX:CSL) led losses on the Australian bourse so far this year at AU$23.2 billion, while ResMed (ASX:RMD) and Cochlear (ASX:COH) followed with losses of AU$10.6 billion, the Australian Financial Review reported Monday, citing Global X ETFs.Negative performing companies on the S&P/ASX 200 index collectively wiped out over AU$217 billion, said Marc Jocum, senior product and investment strategist at Global X ETFs.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

ASX:COHASX:CSLASX:RMD
Asia

CSL Shares Hit Nearly 9-Year Low as US Drops Flu Vaccine Mandate

CSL (ASX:CSL) shares dropped 6% to their lowest since August 2017 after US Secretary of War Pete Hegseth on Tuesday said the mandatory flu vaccine requirement for the joint force has been discarded, effective immediately, according to a video posted on his X account.

ASX:CSL
Asia

PolyNovo Appoints Chief Scientific Officer

PolyNovo (ASX:PNV) appointed Marthe D'Ombrain as chief scientific officer, effective June 1, according to a Wednesday filing with the Australian bourse.D'Ombrain most recently served as executive director and head of global research innovation at CSL (ASX:CSL), the filing added.

ASX:CSLASX:PNV